Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study

Inclusion Criteria

• •Age \> 18 years
• •A diagnosis of a PCN confirmed by EUS-FNA including cyst fluid next generation sequencing (NGS) and/or EUS-guided needle-based confocal laser endomicroscopy (nCLE) and/or EUS- guided through-the-needle biopsy (TTNB)
• •The pancreatic cystic lesion (PCL) measures at least 2 cm in diameter on either CT or MRI/MRCP or EUS and demonstrates concerning worrisome and/or high-risk features as defined by International Consensus Guidelines (2017 revised Fukuoka Guidelines)
• •The patient is not a surgical candidate. Common clinical scenarios include -
• •* Cirrhosis of the liver (common clinical scenario)
• •* Advanced ( \>= 75 years) age (common clinical scenario)
• •* Morbid obesity
• •* Significant cardiorespiratory comorbidity
• •* Patient's choice (patient elects for non-surgical management)
• •* Other significant comorbid conditions that impose prohibitive surgical risks
• •Estimated life expectancy of at least 1 year
• •Capable of giving written informed consent or has a legally authorized representative (LAR) to consent for them
• •Women of childbearing potential must have a negative pregnancy test (serum/urine) on the day of treatment. Pregnancy testing is the routine standard of care practice in the endoscopy laboratory for all patients undergoing endoscopy and sedation for endoscopy
• •The patient prefers non-surgical management after consultation with hepato-pancreato-biliary (HPB) surgery
• •The patient is not a surgical candidate and has had prior attempts at ablation of the PCN by EUS-guided injection of chemotherapy (Ohio State University \[OSU\] Institutional Review Board \[IRB\] protocol 2020C0198)